On Could 15, 2026, Boxer Capital Administration disclosed a brand new place in Corvus Prescription drugs (NASDAQ:CRVS)buying 1,100,000 shares within the first quarter for an estimated $17.55 million primarily based on quarterly common pricing.
What occurred
In response to a May 15, 2026, SEC filingBoxer Capital Administration disclosed a brand new place in Corvus Prescription drugs (NASDAQ:CRVS) by buying 1,100,000 shares over the primary quarter. The estimated transaction worth is $17.55 million, calculated utilizing the common closing value for the interval. The fund reported a quarter-end place worth of $16.09 million for Corvus Prescription drugs, reflecting each share accumulation and value shifts.
What else to know
-
This was a brand new place for Boxer Capital Administration, representing 2.11% of March 31, 2026, reportable AUM.
-
High 5 holdings after the submitting:
-
NASDAQ:TNGX: $227.53 million (29.9% of AUM)
-
NASDAQ:KOD: $51.88 million (6.8% of AUM)
-
NASDAQ:RVMD: $48.62 million (6.4% of AUM)
-
NASDAQ:KYMR: $27.41 million (3.6% of AUM)
-
NASDAQ:CELC: $25.68 million (3.4% of AUM)
-
-
As of Could 14, 2026, Corvus Prescription drugs shares had been priced at $13.66, up 250% over the previous yr, outperforming the S&P 500’s roughly 25% achieve.
Firm overview
|
Metric |
Worth |
|---|---|
|
Value (as of market shut Could 14, 2026) |
$13.66 |
|
Market Capitalization |
$1 billion |
|
Web Earnings (TTM) |
($15.3 million) |
Firm snapshot
-
Corvus Prescription drugs develops immuno-oncology therapies, with lead candidates together with Mupadolimab (CPI-006) for non-small cell lung most cancers and head and neck cancers, CPI-818 for malignant T-cell lymphomas, and Ciforadenant (CPI-444) for superior renal cell most cancers.
-
The corporate operates a clinical-stage biopharmaceutical mannequin, producing worth via the event and potential commercialization of proprietary monoclonal antibodies and small-molecule medicine focusing on most cancers and immune-related ailments.
-
Corvus Prescription drugs collaborates strategically with companions to advance its pipeline and tackle unmet wants in oncology and immune-related circumstances.
Corvus Prescription drugs is a clinical-stage biotechnology firm targeted on creating progressive immunotherapies for most cancers remedy. Leveraging a pipeline of monoclonal antibodies and small molecule antagonists, the corporate goals to deal with unmet wants in oncology via strategic analysis and scientific growth. Its aggressive edge lies in its focused strategy to immune modulation and strategic collaborations to advance its portfolio.
What this transaction means for traders
Boxer Capital’s willingness to construct a large stake in Corvus throughout a fairly large run for the agency’s inventory actually looks like a powerful vote of confidence. Corvus has more and more shifted investor consideration towards atopic dermatitis, the place recent Phase 1 data confirmed sturdy responses with out important rebound after remedy stopped. In a single cohort, 75% of sufferers achieved EASI 75 responses, whereas the corporate additionally highlighted biomarker knowledge suggesting the potential for “drug-free remissions.” The corporate has already launched a Section 2 trial anticipated to enroll roughly 200 sufferers.
Financially, Corvus ended the quarter with $236.7 million in money and marketable securities after elevating roughly $189 million earlier this yr, which administration says ought to fund operations into the second quarter of 2028. In the meantime, the corporate posted a quarterly web lack of $13.7 million as R&D spending climbed alongside increasing trials.
For long-term traders, the important thing query going ahead is whether or not soquelitinib’s early immune-reset narrative can maintain up in bigger research. If it does, Corvus might change into way more than a small oncology biotech.
